$103.87
Value $180B
ABT and LGND stock compared: price, dividend, valuation and results, from SEC filings.
$103.87
Value $180B
$286.94
Value $5.7B
Abbott Laboratories (ABT) has a market value of $180B and Ligand Pharmaceuticals (LGND) $5.7B. Over the last year, with dividends, ABT moved -18.1% and LGND +38.6%. The P/E is 38.4 for ABT and 111.2 for LGND. Dividend yield: ABT 2.43%, LGND none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$180B
LGND$5.7B
ABT is 32 times LGND
Revenue, 12 months
ABT$48.2B
LGND$254M
ABT is 190 times LGND
Net income, 12 months
ABT$4.7B
LGND$51M
ABT is 91 times LGND
Operating margin
ABT13.8%
LGND9.3%
4.5 points apart
ROIC
ABT6.3%
LGND1.3%
5.0 points apart
P/E
ABT38.4
LGND111.2
LGND is 2.9 times ABT
Dividend yield
ABT2.4%
LGND0.0%
2.4 points apart
5-year return
ABT-10.1%
LGND+186.2%
196.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-10.1%
LGND+186.2%
| Period | ABTWith dividends | LGNDWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | -18.1%Price -20.1% | +38.6%Price +38.6% |
| 3 years since November 17, 2023 | +11.1%+3.6% a yearPrice +4.3% | +396.3%+70.6% a yearPrice +396.3% |
| 5 years since November 18, 2021 | -10.1%-2.1% a yearPrice -18.6% | +186.2%+23.4% a yearPrice +186.2% |
| 10 years since November 21, 2016 | +215.2%+12.2% a yearPrice +161.2% | +328.7%+15.7% a yearPrice +328.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesLGNDLigand Pharmaceuticals
| Price | $103.87 | $286.94 |
|---|---|---|
| Market value | $180B | $5.7B |
| Enterprise value (EV) | $207B | $6.4B |
| P/E | 38.4 | 111.2 |
| P/E, 5-year median | 33.7 | 30.8 |
| P/B | 3.5 | 6.0 |
| EV/EBIT | 31.2 | 271.4 |
| Free cash flow yield | 3.7% | 1.6% |
| Revenue, 12 months | $48.2B | $254M |
|---|---|---|
| Net income, 12 months | $4.7B | $51M |
| Free cash flow, 12 months | $6.8B | $91M |
| Earnings per share, 12 months | $2.69 | $2.30 |
| Revenue growth, year on year | 5.7% | 60.4% |
| Revenue growth a year, past | +5.1%over 5 years | +10.4%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | – |
|---|---|---|
| Operating margin | 13.8% | 9.3% |
| Net margin | 9.8% | 20.3% |
| ROIC | 6.3% | 1.3% |
| ROE | 9.1% | 5.3% |
| Cash | $4.3B | $447M |
|---|---|---|
| Total debt | $31.2B | $1.2B |
| Net debt / EBITDA | 3.3 | 11.9 |
| Interest cover | 6.7× | 2.9× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | 0.3% |
| Shareholder yield | 2.9% | 0.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($180B) is about 31.5 times Ligand Pharmaceuticals ($5.7B), at today's prices.
Since November 21, 2016, ABT's price moved +161.2% and LGND's +328.7%. With dividends: ABT +215.2% (+12.2% a year), LGND +328.7% (+15.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.43% for Abbott Laboratories and none for Ligand Pharmaceuticals. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.4 for ABT and 111.2 for LGND. The median of the last five years was 33.7 and 30.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 20.3% for Ligand Pharmaceuticals, and the operating margin 13.8% and 9.3%. Revenue was $48.2B and $254M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.